GSK's RSV vaccine Arexvy approved in Japan for some adults under 50
(Alliance News) - GSK PLC on Monday announced that Japan's Ministry of Health, Labour & Welfare expanded the eligible population for its respiratory syncytial virus vaccine Arexvy. Read More